Skip to content

Clinical trial on Kerala Ayurveda product in Tiredness subjects

A prospective, interventional, open-label clinical study to evaluate the safety and efficacy of KAL-HS-02 in reducing fatigue (Shrama), tiredness (Klama), improving strength (Balya), energy (Urjas) and enhancing quality of life (Swasthakara) among adult volunteers

Status
Recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/11/047555
Enrollment
40
Registered
2022-11-23
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R531- Weakness Health Condition 2: R531- Weakness

Interventions

None listed

Sponsors

Kerala Ayurveda Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age between 18 to 60 years 2. Both male and female 3. Subject meet criteria for fatigue as per Chalder Fatigue Assessment scale. 4. Subjects willing and able to provide informed consent voluntarily 5. Patient is willing and able to comply with all trial requirements

Exclusion criteria

Exclusion criteria: 1. Pregnant or Breast feeding. 2. Inability to provide voluntary consent. 3. Volunteers who have participated in any drug research study within past 3 months 4. Patients with pre existing severe systemic disease like uncontrolled diabetes, hypertension, and Cardiac illness etc necessitating long term medication. 5. Evidence of significant uncontrolled co morbid disease which in the investigators opinion would jeopardize patient participation. 6. Any clinically significant medical history, medical finding or an ongoing medical or psychiatric condition exists which in the opinion of the Investigator could jeopardize the safety of the subject, impact validity of the study results or interfere with the completion of study according to the protocol. 7. History of cancer, including solid tumors, hematologic malignancies and carcinoma in situ 8. Use of any anti psychotic drugs in the past. 9. Subjects who abuse drugs or alcohol 10. Use of any investigational medication within 4 weeks prior to start of study drug

Design outcomes

Primary

MeasureTime frame
1.% Improvement in Chalder Fatigue Scale (CFQ 11) (Time points: Baseline, Day 7, Day 14, Day 28) 2.% Improvement in energy/fatigue scale of the RAND-36 questionnaire. (Time points: Baseline, Day 7, Day 14, Day 28) Timepoint: Day 0day 7 ,Da 14 and Day 28

Secondary

MeasureTime frame
1. Assessment of Total energy expenditure and Physical Activity (IPAQ Questionnaire)Timepoint: Baseline (Day 0) and Day 28

Countries

India

Contacts

Public ContactDrSarala Samuel

Kerala Ayurveda Ltd.

jayashree@keralaayurveda.us9880677814

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026